Spots Global Cancer Trial Database for gw572016
Every month we try and update this database with for gw572016 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma | NCT00883688 | Brain Cancer Pediatric Cance... | Bevacizumab Lapatinib | - 21 Years | M.D. Anderson Cancer Center | |
| INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients | NCT00455039 | Breast Cancer | GW572016 | - | University of New Mexico | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval | NCT01328054 | Cancer | lapatinib placebo matchin... | 18 Years - | GlaxoSmithKline | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer | NCT00263588 | Neoplasms, Brea... | lapatinib | 18 Years - | Novartis | |
| Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer | NCT00356811 | Neoplasms, Brea... | Lapatinib oral ... Paclitaxel infu... | 18 Years - | GlaxoSmithKline | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer | NCT00089999 | Neoplasms, Brea... | Lapatinib | 18 Years - | GlaxoSmithKline | |
| GW572016 For Treatment Of Refractory Metastatic Breast Cancer | NCT00062686 | Neoplasms, Brea... | GW572016 | 18 Years - | GlaxoSmithKline | |
| A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval | NCT01328054 | Cancer | lapatinib placebo matchin... | 18 Years - | GlaxoSmithKline | |
| EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | NCT00338247 | Neoplasms, Brea... | lapatinib + cap... | 18 Years - | Novartis | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Neoadjuvant GW572016 to Treat Breast Cancer | NCT00206427 | Breast Cancer | GW572016 lapatinib | 18 Years - | Baylor Breast Care Center | |
| INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients | NCT00455039 | Breast Cancer | GW572016 | - | University of New Mexico | |
| Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer | NCT00089999 | Neoplasms, Brea... | Lapatinib | 18 Years - | GlaxoSmithKline | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| GW572016 For Treatment Of Refractory Metastatic Breast Cancer | NCT00062686 | Neoplasms, Brea... | GW572016 | 18 Years - | GlaxoSmithKline | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients | NCT00455039 | Breast Cancer | GW572016 | - | University of New Mexico |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
